Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

This tool allows you to determine the current value and the yield of a given amount of stock invested in the past. Fill in the amount invested or amount of the stock, as well as the purchase date, in ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Explore opportunities with Novartis below.

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

Chronic spontaneous urticaria (CSU) is a serious condition that affects approximately 1.7 million people in the United States and is characterized by itchy hives, deep tissue swelling (angioedema), or ...

诺华 承 诺 与残障人士共事并 为 他 们 提供合理的便利 设 施。如果您由于健康状况或残障 在招聘 过 程的任何 环 节 需要合理便利 设 施 或者 为 了履行 职 位的基本 职 能 请发 送 电 子 邮 件 ...

Εξερευνήστε ευκαιρίες στη Novartis και στη Sandoz παρακάτω. Για επιπλέον ρόλους στη Novartis Gene Therapies (πρώην AveXis) επισκεφτείτε την Αναζήτηση ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.